Tumour-initiating cell-specific miR-1246 and miR-1290 expression converge to promote non-small cell lung cancer progression
Citations Over TimeTop 10% of 2016 papers
Abstract
The tumour-initiating cell (TIC) model accounts for phenotypic and functional heterogeneity among tumour cells. MicroRNAs (miRNAs) are regulatory molecules frequently aberrantly expressed in cancers, and may contribute towards tumour heterogeneity and TIC behaviour. More recent efforts have focused on miRNAs as diagnostic or therapeutic targets. Here, we identified the TIC-specific miRNAs, miR-1246 and miR-1290, as crucial drivers for tumour initiation and cancer progression in human non-small cell lung cancer. The loss of either miRNA impacted the tumour-initiating potential of TICs and their ability to metastasize. Longitudinal analyses of serum miR-1246 and miR-1290 levels across time correlate their circulating levels to the clinical response of lung cancer patients who were receiving ongoing anti-neoplastic therapies. Functionally, direct inhibition of either miRNA with locked nucleic acid administered systemically, can arrest the growth of established patient-derived xenograft tumours, thus indicating that these miRNAs are clinically useful as biomarkers for tracking disease progression and as therapeutic targets.
Related Papers
- → MicroRNA-21 versus microRNA-34: Lung cancer promoting and inhibitory microRNAs analysed in silico and in vitro and their clinical impact(2017)22 cited
- → Therapeutic modulation of microRNAs(2013)2 cited
- → Προσδιορισμός κυκλοφορούντων oncomiRs και angiomiRs στο αίμα ασθενών με καρκίνο και διερεύνηση της διαγνωστικής, προγνωστικής και προβλεπτικής τους ικανότητας(2016)
- → microRNAs in plasma as biomarkers for Parkinson’s disease(2018)
- Expression profiles of miRNAs in human pancreatic cancer cell lines(2009)